PRognostic factor of Early Death In phase II Trials or the end of ‘sufficient life expectancy’ as an inclusion criterion? (PREDIT model)

BACKGROUND: Optimizing patient selection is a necessary step to design better clinical trials. ‘Life expectancy’ is a frequent inclusion criterion in phase II trial protocols, a measure that is subjective and often difficult to estimate. The aim of this study was to identify factors associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Grellety, Thomas, Cousin, Sophie, Letinier, Louis, Bosco-Lévy, Pauline, Hoppe, Stéphanie, Joly, Damien, Penel, Nicolas, Mathoulin-Pelissier, Simone, Italiano, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050995/
https://www.ncbi.nlm.nih.gov/pubmed/27716199
http://dx.doi.org/10.1186/s12885-016-2819-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5050995/
https://www.ncbi.nlm.nih.gov/pubmed/27716199
http://dx.doi.org/10.1186/s12885-016-2819-7

Ejemplares similares